HIV integrase inhibitors (Formulary)

DOLUTEGRAVIR

Important: Therapy notes

  • MHRA alert:Dolutegravir (Tivicay, Triumeq, Juluca): updated advice on increased risk of neural tube defects (October 2020)
  • Homecare is the preferred option - contact nhsh.homecare@nhs.scot

Important: Formulation and dosage details

Formulation:

Tablets 10mg, 25mg, 50mg (hospital use only)

ELVITEGRAVIR

Important: Therapy notes

  • MHRA alert: Elvitegravir boosted with cobicistat: avoid use in pregnancy due to risk of treatment failure and maternal-to-child transmission of HIV-1 (April 2019)

Important: Formulation and dosage details

Formulation:

Given as part of the Genvoya and the Stribild combinations.

RALTEGRAVIR

Important: Therapy notes

Important: Formulation and dosage details

Formulation:

Tablets 400mg, 600mg (hospital use only)

Editorial Information

Document Id: F280